ArticlePediatric nephrology (Berlin, Germany)2014
Tolvaptan therapy for massive edema in a patient with nephrotic syndrome.
Article in Pediatric nephrology (Berlin, Germany), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 35 citations in OpenAlex.
- Dual Impact of Tolvaptan on Intracellular and Extracellular Water in Chronic Kidney Disease Patients with Fluid Retention.Internal medicine (Tokyo, Japan)Trial
- A new frontier in edema management: the potential of tolvaptan for refractory edema with hyponatremia in pediatric nephrotic syndrome.Clinical and experimental nephrology · 2026Article
- Pharmacodynamics Research on Danggui-Shaoyao-San through Body Fluid Indexes of Spleen Deficiency-water Dampness Rats using Bio-impedance Technology.Current pharmaceutical biotechnology · 2024Article
- Efficacy of oral tolvaptan for severe edema and hyponatremia in a patient with refractory nephrotic syndrome.CEN case reports · 2021Article
- Mechanisms and management of edema in pediatric nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2021Review
- Tolvaptan Response in a Hyponatremic Newborn with Syndrome of Inappropriate Secretion of Antidiuretic Hormone.Case reports in pediatrics · 2021Article
- Current Perspectives in Management of Edema in Nephrotic Syndrome.Indian journal of pediatrics · 2020Review
- Tolvaptan therapy to treat severe hyponatremia in pediatric nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2020Article
- Impact of serum albumin levels on the body fluid response to tolvaptan in chronic kidney disease patients.International urology and nephrology · 2019Article
- Efficiency of Single Dose of Tolvaptan Treatment During the Triphasic Episode After Surgery for CraniopharyngiomaJournal of clinical research in pediatric endocrinology · 2019Article
- Focus on neonatal and infantile onset of nephrogenic syndrome of inappropriate antidiuresis: 12 years later.Pediatric nephrology (Berlin, Germany) · 2019Review
- Impaired Renal Function May Not Negate the Efficacy of Tolvaptan in the Treatment of Cirrhotic Patients with Refractory Ascites.Clinical drug investigation · 2019Article
- Effects of tolvaptan on urine output in hospitalized heart failure patients with hypoalbuminemia or proteinuria.Heart and vessels · 2018Article
- Nephrotic Syndrome: Oedema Formation and Its Treatment With Diuretics.Frontiers in physiology · 2018Review
- Tolvaptan Treatment in Children with Chronic Hyponatremia due to Inappropriate Antidiuretic Hormone Secretion: A Report of Three CasesJournal of clinical research in pediatric endocrinology · 2017Review
- The non-immunosuppressive management of childhood nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2016Review
- Tolvaptan use during hyperhydration in paediatric intracranial lymphoma with SIADH.Endocrinology, diabetes & metabolism case reports · 2016Article
- Vasopressin receptor antagonists.Current hypertension reports · 2015Review
- Draining the edema: a new role for aquaretics?Pediatric nephrology (Berlin, Germany) · 2014Article
- Therapy with the Combination of Tolvaptan and Furosemide for Refractory Edema in Nephrotic Syndrome.Indian journal of nephrologyArticle
Corrections and comments
- Commented on by
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNephrotic syndrome (NS) is characterized by water and sodium retention, which leads to edema. The non-osmotic stimulation of arginine vasopressin release from the pituitary gland has been implicated as one of the important factors in abnormal water retention in patients with NS. CASE-DIAGNOSIS/TREATMENT: We present the initial description of a patient with massive edema caused by refractory nephrotic syndrome, which was effectively treated with tolvaptan, a selective oral vasopressin V2 receptor antagonist.
conclusionsTolvaptan is effective for the treatment of massive edema caused by NS. Larger studies are needed in the future to fully assess the value and safety of tolvaptan use for this condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.